October 6, 2026
For generations, women have too often been asked to accept gaps in medical knowledge about their health as simply a fact of life.
Pain that goes unexplained. Conditions that go undiagnosed. Symptoms dismissed or normalized. Treatments prescribed without adequate understanding of how certain conditions may affect women differently than men.
But as medical treatments and breakthroughs continue to advance, New Jersey’s life sciences play an enormous role in making sure women are not merely an afterthought in research, innovation, or care.
New Jersey, called the “Medicine Chest of the World,” hosts a life sciences ecosystem that drives change. Biopharmaceutical, medical device, technology, and diagnostics companies aim to discover new treatments and cures, saving lives and improving outcomes worldwide – translating science into better patient care.
Women’s health is one of the most important opportunities for continued research and discovery.
Consider clinical trials. Clinical research is the foundation for determining whether new treatments are safe and effective. Yet ensuring that women are appropriately represented in research – and that women from diverse communities have meaningful opportunities to participate – remains an ongoing challenge.
The answer is not simply to recruit more participants. We need to understand why women may not hear about trials, what barriers prevent participation, how providers and researchers communicate with potential participants, and how industry, health systems, and community organizations can build greater trust.
Representation matters because better science depends on understanding the people who will ultimately receive the treatment.
And women’s health cannot be defined solely by reproductive health. Or breast cancer. Or osteoporosis.
Heart disease and stroke remain major threats to women. So do cancer and neurodegenerative diseases such as Alzheimer’s. Women can experience diseases very differently from men, face different risk factors, and encounter distinct barriers to diagnosis and treatment. The more we understand those differences, the better medical advances will be for everyone.
Perhaps nowhere is this need more apparent than menopause.
Millions of women experience perimenopause and menopause, yet too many still struggle to find straightforward information, appropriate treatment, and clinicians equipped to address their needs. For years, menopause was treated as something women simply had to endure rather than as a significant stage of health deserving serious scientific attention.
That is beginning to change.
Researchers and life sciences companies have long explored new hormonal and non-hormonal therapies, digital health tools, and more integrated approaches to care. Innovation is helping move the conversation from “just live with it” to “let’s understand it, study it, and treat it.”
That progress is encouraging – but it’s only a beginning.
